Tales from opposite corners of the world: Emergency department opt-out testing: A cost-effective route to earlier HIV and Hepatitis diagnosis in Australia and Germany
Australia and Germany have both made progress toward HIV and viral hepatitis elimination targets, yet a significant share of infections remains undiagnosed. These levels of undiagnosed infection indicate that standard blood-borne virus (BBV) testing approaches are not sufficient to meet public health goals. Emergency department opt-out testing European and US studies demonstrate the cost-effectiveness and Read More >
Estimating the number of people who could benefit from HIV pre-exposure prophylaxis (PrEP) in England and the unmet need
In 2019, the previous government committed to eliminating HIV transmission by 2030 [1]. An action plan was developed [2] and a funding commitment made for opt-out HIV testing in hospital A&Es. However, despite the recent progress made in HIV prevention and treatment, England is not predicted to achieve the 2030 zero-transmission target under the current Read More >
Estimating the potential health economic value of introducing universal opt-out testing for HIV in emergency departments in Italy
Italy faces challenges with late HIV diagnoses, which leads to worse health outcomes and higher healthcare costs. In Italy, the proportion of late diagnoses (i.e., a CD4 count <350 cells/mm3) has increased to 60% in 2020—10% higher than the European average (1). With an estimated 13,000–15,000 undiagnosed HIV cases in Italy, innovative testing strategies are urgently needed Read More >
When will the UK achieve HIV transmission elimination? Modelling the impact of current HIV prevention efforts on progress towards the 2030 elimination goal
In 2019, the previous UK government set the ambitious target of eliminating HIV transmission within the UK by 2030. While great progress has been made in HIV prevention and treatment in the UK, with England reaching the UNAIDS 95-95-95 target in 20231, past evidence suggested that the goal of ‘elimination’ by 2030 is unlikely to Read More >
An Implementation Tool For US Professionals: First Void Urine Self-Sampling for Primary HPV Cervical Cancer Screening
The national coverage of cervical cancer screening in the US is falling, with about 1 in 4 women not up to date with screening1. Under-screened women bear the greatest burden of disease. Evidence shows 60-64% of American women diagnosed with cervical cancer were unscreened, highlighting the need to explore alternative methods to improve access2-4. In Read More >
Publication of our economic evaluation comparing two cervical screening strategies in Belgium: HPV primary versus co-testing
User experience and workflow performance: a pilot evaluation of the Genius Digital Diagnostics System for screening cervical cytology samples
Evaluating the benefits and costs of using an mRNA versus DNA HR-HPV assay in the National Cervical Screening Programme in the Netherlands
Modelling the impact of using a DNA compared to mRNA HPV assay as part of the cervical screening programmes in Sweden and Denmark
Evaluating the choice of HPV assay in the French cervical screening programme with a decision tree model
